ЛИПОПРОТЕИН (A) В СОВРЕМЕННОЙ КAРДИОЛОГИИ

Despite adequate lipid-lowering therapy the rate of cardiovascular complications is still high. One of the main factors influencing the residual risk in patients with atherogenic dyslipidemia, along with elevated triglycerides and reduced cholesterol of high-density lipoproteins is lipoprotein (a). The paper reviews the current conception of the impact of lipoprotein (a) on the development and progression of atherosclerosis, as well as the main methods of treatment, including lipid apheresis.